Cargando…
PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429536/ http://dx.doi.org/10.1097/01.HS9.0000975240.90137.21 |
| _version_ | 1785090739297845248 |
|---|---|
| author | Ye, Jing Christine Biran, Noa Nair, Sandhya Lin, Xiwu Qi, Keqin Londhe, Anil Ammann, Eric Renaud, Thomas Kane, Colleen Parekh, Trilok Gray, Kathleen Peterson, Steve Costa, Luciano |
| author_facet | Ye, Jing Christine Biran, Noa Nair, Sandhya Lin, Xiwu Qi, Keqin Londhe, Anil Ammann, Eric Renaud, Thomas Kane, Colleen Parekh, Trilok Gray, Kathleen Peterson, Steve Costa, Luciano |
| author_sort | Ye, Jing Christine |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429536 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104295362023-08-17 PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA Ye, Jing Christine Biran, Noa Nair, Sandhya Lin, Xiwu Qi, Keqin Londhe, Anil Ammann, Eric Renaud, Thomas Kane, Colleen Parekh, Trilok Gray, Kathleen Peterson, Steve Costa, Luciano Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429536/ http://dx.doi.org/10.1097/01.HS9.0000975240.90137.21 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Ye, Jing Christine Biran, Noa Nair, Sandhya Lin, Xiwu Qi, Keqin Londhe, Anil Ammann, Eric Renaud, Thomas Kane, Colleen Parekh, Trilok Gray, Kathleen Peterson, Steve Costa, Luciano PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title | PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full | PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_fullStr | PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full_unstemmed | PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_short | PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_sort | pb2117: talquetamab vs real-world physician’s choice of therapy: comparative effectiveness in patients with triple-class exposed relapsed/refractory multiple myeloma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429536/ http://dx.doi.org/10.1097/01.HS9.0000975240.90137.21 |
| work_keys_str_mv | AT yejingchristine pb2117talquetamabvsrealworldphysicianschoiceoftherapycomparativeeffectivenessinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT birannoa pb2117talquetamabvsrealworldphysicianschoiceoftherapycomparativeeffectivenessinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT nairsandhya pb2117talquetamabvsrealworldphysicianschoiceoftherapycomparativeeffectivenessinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT linxiwu pb2117talquetamabvsrealworldphysicianschoiceoftherapycomparativeeffectivenessinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT qikeqin pb2117talquetamabvsrealworldphysicianschoiceoftherapycomparativeeffectivenessinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT londheanil pb2117talquetamabvsrealworldphysicianschoiceoftherapycomparativeeffectivenessinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT ammanneric pb2117talquetamabvsrealworldphysicianschoiceoftherapycomparativeeffectivenessinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT renaudthomas pb2117talquetamabvsrealworldphysicianschoiceoftherapycomparativeeffectivenessinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT kanecolleen pb2117talquetamabvsrealworldphysicianschoiceoftherapycomparativeeffectivenessinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT parekhtrilok pb2117talquetamabvsrealworldphysicianschoiceoftherapycomparativeeffectivenessinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT graykathleen pb2117talquetamabvsrealworldphysicianschoiceoftherapycomparativeeffectivenessinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT petersonsteve pb2117talquetamabvsrealworldphysicianschoiceoftherapycomparativeeffectivenessinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT costaluciano pb2117talquetamabvsrealworldphysicianschoiceoftherapycomparativeeffectivenessinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma |